Changchun High-Tech: Jinbeixin Achieves Strong Sales Since Mid-July Launch After June 2025 Approval

Deep News

2025/10/31

Changchun High-Tech Industry (Group) Co., Ltd. announced on October 31 that Jinbeixin, approved in late June 2025, commenced sales in mid-July and has demonstrated robust performance. The product generated over CNY 55 million in revenue during Q3 2025. The company has established a 200-member sales team and is rapidly expanding hospital and channel coverage.

For Mesia, targeting cancer-related anorexia-cachexia, promotional efforts over the past year have driven sales close to CNY 100 million in the first three quarters of 2025. The company plans to enhance promotion further, aligning with national medical insurance negotiations to boost awareness among hospitals, doctors, and patients.

Moving forward, Changchun High-Tech will focus resources on high-potential new products to diversify its business and drive growth.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1126490787"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1126490787\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1126490787?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 17:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126490787","market":"nz","top_or_hot":-1,"title":"Changchun High-Tech: Jinbeixin Achieves Strong Sales Since Mid-July Launch After June 2025 Approval","media":"Deep News","content":"<p>Changchun High-Tech Industry (Group) Co., Ltd. announced on October 31 that Jinbeixin, approved in late June 2025, commenced sales in mid-July and has demonstrated robust performance. The product generated over CNY 55 million in revenue during Q3 2025. The company has established a 200-member sales team and is rapidly expanding hospital and channel coverage.</p>\n<p>For Mesia, targeting cancer-related anorexia-cachexia, promotional efforts over the past year have driven sales close to CNY 100 million in the first three quarters of 2025. The company plans to enhance promotion further, aligning with national medical insurance negotiations to boost awareness among hospitals, doctors, and patients.</p>\n<p>Moving forward, Changchun High-Tech will focus resources on high-potential new products to diversify its business and drive growth.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Changchun High-Tech: Jinbeixin Achieves Strong Sales Since Mid-July Launch After June 2025 Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChangchun High-Tech: Jinbeixin Achieves Strong Sales Since Mid-July Launch After June 2025 Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-10-31 17:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Changchun High-Tech Industry (Group) Co., Ltd. announced on October 31 that Jinbeixin, approved in late June 2025, commenced sales in mid-July and has demonstrated robust performance. The product generated over CNY 55 million in revenue during Q3 2025. The company has established a 200-member sales team and is rapidly expanding hospital and channel coverage.</p>\n<p>For Mesia, targeting cancer-related anorexia-cachexia, promotional efforts over the past year have driven sales close to CNY 100 million in the first three quarters of 2025. The company plans to enhance promotion further, aligning with national medical insurance negotiations to boost awareness among hospitals, doctors, and patients.</p>\n<p>Moving forward, Changchun High-Tech will focus resources on high-potential new products to diversify its business and drive growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0075","symbol_name":"新三板","start_time":0,"source_url":"","article_id":"1126490787","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126490787","pubTimestamp":1761903032,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Changchun High-Tech Industry (Group) Co., Ltd. announced on October 31 that Jinbeixin, approved in late June 2025, commenced sales in mid-July and has demonstrated robust performance. The product...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0075":"新三板","BK0188":"融资融券","BK0028":"国家队","BK0046":"生物疫苗","000661":"长春高新","BK0057":"长吉图板块","BK0239":"医药制造"},"translate_title":"长春高新：金贝芯2025年6月获批后7月中旬上市以来实现强劲销售","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"91272":1,"000661":1},"content_text":"Changchun High-Tech Industry (Group) Co., Ltd. announced on October 31 that Jinbeixin, approved in late June 2025, commenced sales in mid-July and has demonstrated robust performance. The product generated over CNY 55 million in revenue during Q3 2025. The company has established a 200-member sales team and is rapidly expanding hospital and channel coverage.\nFor Mesia, targeting cancer-related anorexia-cachexia, promotional efforts over the past year have driven sales close to CNY 100 million in the first three quarters of 2025. The company plans to enhance promotion further, aligning with national medical insurance negotiations to boost awareness among hospitals, doctors, and patients.\nMoving forward, Changchun High-Tech will focus resources on high-potential new products to diversify its business and drive growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}